Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress

Elicera Therapeutics AB

21/04/2026 07:12

Overview

Sweden cell and gene therapy developer's Q1 operating loss narrowed from a year earlier

Q1 loss per share narrowed to SEK -0.10 from SEK -0.22

Company reported positive clinical data and new patent for ELC-401 CAR T-cell program

Outlook

Company expects first glioblastoma patient in ELC-401 trial to be treated during 2027

Elicera continues preparations for ELC-401 clinical trial and is seeking soft financing

Next steps in ELC-100 program under evaluation; out-licensing opportunities being considered

Result Drivers

CARMA STUDY DATA - Co reported promising clinical results in the CARMA study, including high rates of complete metabolic response and no serious side effects

ELC-401 PROGRESS - Co advanced its ELC-401 CAR T-cell program with preclinical development completion, clinical trial planning, and Japanese patent approval

Company press release: ID:nWkr6vCtlJ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
-SEK 0.10


Analyst Coverage

Wall Street's median 12-month price target for Elicera Therapeutics AB is SEK8.20, about 62.1% above its April 20 closing price of SEK5.06

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)